These 10 Stocks Are Making Big Moves

4. Viking Therapeutics, Inc. (NASDAQ:VKTX)

Viking Therapeutics jumped by 9.74 percent on Tuesday to close at $30.19 apiece as investors repositioned portfolios ahead of the expected release of the results of its own weight loss drug clinical trial.

In a statement, Viking Therapeutics, Inc. (NASDAQ:VKTX) said it expects to report the phase 2 trial data for its weight loss drug candidate VK2735 after 13 weeks of trial. The trial enrolled late in March approximately 280 obese adults with at least one weight-related co-morbid condition.

The primary endpoint of the study is to find the percentage change in body weight from baseline after 13 weeks of treatment. Secondary and exploratory endpoints will evaluate a range of additional safety and efficacy measures.

Viking Therapeutics, Inc. (NASDAQ:VKTX) previously reported positive results from a 28-day Phase 1 multiple ascending dose (MAD) clinical trial of the tablet formulation of VK2735 in healthy volunteers.

According to the company, receiving VK2735 demonstrated dose-dependent reductions in mean body weight from baseline, ranging up to 8.2 percent.